<DOC>
	<DOCNO>NCT01473316</DOCNO>
	<brief_summary>This open-label , fixed-sequence , single-center , 2 period study . The study design determine effect ketoconazole pharmacokinetics GDC-0980 .</brief_summary>
	<brief_title>Study Determine Effect Ketoconazole Pharmacokinetics GDC-0980</brief_title>
	<detailed_description />
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Healthy postmenopausal and/or surgically sterile adult nonsmoking female subject 18 65 year age , inclusive , body mass index 18 32 kg/m2 , inclusive Medically healthy determine absence clinically significant finding physical examination , medical history , vital sign measurement , clinical laboratory test , 12 lead electrocardiogram ( ECGs ) determine investigator Female subject nonchildbearing potential History clinical manifestation significant metabolic ( include type 1 2 diabetes ) , hepatic , renal , hematological ( include hypercholesterolemia triglyceridemia ) , pulmonary , cardiovascular , endocrine , gastrointestinal ( include gastric duodenal ulcer ) , urological , neurological , psychiatric disorder , cancer History inflammatory arthritis History symptomatic hypotension History severe physical injury , direct impact trauma , neurological trauma within 6 month Day 1 Period 1 History seizure disorder History bipolar major depressive disorder History stomach intestinal surgery resection could potentially alter absorption and/or excretion orally administer drug , exception appendectomy , hernia repair , cholecystectomy , allow History active liver disease , include hepatitis cirrhosis History presence abnormal ECG History ventricular dysrhythmias risk factor ventricular dysrhythmias Abnormality chest xray Screening determine clinically significant investigator medical monitor History alcoholism , drug abuse , drug addiction Used nicotinecontaining nicotinereplacement product within 6 month Day 1 Period 1 Participated investigational drug study receipt investigational study drug occur within 1 month 5 halflives Day 1 Period 1 Used prescription medications/products include monoamine oxidase inhibitor , thioridazine , pimozide , antidepressant within 1 month ( 2 week antibiotic ) Day 1 Period 1 , exception hormone replacement therapy 2 week ' use narcotic pain , unless deem acceptable investigator Used medication capable inhibit hepatic enzyme within 1 month 5 halflives Day 1 Period 1 Received vaccination immunization within 1 month Day 1 Period 1 Used proton pump inhibitor histamine H2 receptor antagonist within 1 month Day 1 Period 1 Known hypersensitivity ketoconazole , azole antifungal Used overthecounter , nonprescription preparation within 7 day Day 1 Period 1 , unless deem acceptable investigator Used alcoholcontaining , grapefruitcontaining , caffeine contain food beverage within 72 hour Day 1 Period 1 , unless deem acceptable investigator Poor peripheral venous access Donated blood within 2 week plasma within 1 week Day 1 Period 1 Received blood product within 2 month Day 1 Period 1 Positive urine drug alcohol screen Positive screen hepatitis B surface antigen , hepatitis C virus , human immunodeficiency virus type 1 2 Diagnosed vitamin B12 deficiency Any acute chronic condition , opinion investigator , would limit subject 's ability complete participate clinical study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>